Home › NCT06144151
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: To be considered eligible for study participation, patient will satisfy all relevant inclusion criteria and none of the exclusion criteria. Inclusion Criteria: 1. Ages Eligible for Study: 18 Years and above (Adult, Older Adult) 2. Sexes Eligible for Study: All 3. Patient with histologically proven DLBCL, PMBCL or tFL, or follicular Lymphoma receiving axi-cel CAR-T cell therapy in the inpatient setting at MD Anderson Cancer Center 4. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Patients who have already been administered CAR-T cell therapy. 2. The patient who is unwilling or unable to comply with the requirements of the study including being able to be assessed with pupillometer 3. Patient has a condition which places him at an unacceptable risk as determined by the investigator
About the study
To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.
What is being tested
- NeurOptics® NPi®-300 Pupillometer (device)
Sponsor: M.D. Anderson Cancer Center · Participants: 100 · Started: Feb 8, 2024
Contact the study team
- Ranjit Nair, MD · Phone: (713) 563-4354
Official record on ClinicalTrials.gov — NCT06144151
Locations in the U.S.
| Texas | MD Anderson Cancer Center, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.